Evidence map›Paper›PMID 26503259›Full record

ArticleJournal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract2016

Minnelide Overcomes Oxaliplatin Resistance by Downregulating the DNA Repair Pathway in Pancreatic Cancer.

Shrey Modi, Devika Kir, Bhuwan Giri, Kaustav Majumder, Nivedita Arora, Vikas Dudeja, Sulagna Banerjee, Ashok K Saluja

Open access · greenAbstract readEvaluation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
6.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 39 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Multi-Pathway Study for Oxaliplatin Resistance Reduction.Current issues in molecular biology · 2025
    Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Modeling pancreatic cancer in mice for experimental therapeutics.Biochimica et biophysica acta. Reviews on cancer · 2021
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Shrey ModiDivision of Basic and Translational Research, Department of Surgery, University of Minnesota, 420 Delaware Street SE, MMC195, Minneapolis, MN, 55455, USA.
Devika KirDivision of Basic and Translational Research, Department of Surgery, University of Minnesota, 420 Delaware Street SE, MMC195, Minneapolis, MN, 55455, USA.
Bhuwan GiriDivision of Basic and Translational Research, Department of Surgery, University of Minnesota, 420 Delaware Street SE, MMC195, Minneapolis, MN, 55455, USA.
Kaustav MajumderDivision of Basic and Translational Research, Department of Surgery, University of Minnesota, 420 Delaware Street SE, MMC195, Minneapolis, MN, 55455, USA.
Nivedita AroraDivision of Basic and Translational Research, Department of Surgery, University of Minnesota, 420 Delaware Street SE, MMC195, Minneapolis, MN, 55455, USA.
Vikas DudejaDivision of Basic and Translational Research, Department of Surgery, University of Minnesota, 420 Delaware Street SE, MMC195, Minneapolis, MN, 55455, USA.
Sulagna BanerjeeDivision of Basic and Translational Research, Department of Surgery, University of Minnesota, 420 Delaware Street SE, MMC195, Minneapolis, MN, 55455, USA.
Ashok K SalujaDivision of Basic and Translational Research, Department of Surgery, University of Minnesota, 420 Delaware Street SE, MMC195, Minneapolis, MN, 55455, USA. asaluja@umn.edu.
University of Minnesota · US

Funding

UAB / UMN SPORE in Pancreatic CancerP50CA101955 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BUCHSBAUM, DONALD J · 2010 to 2014
$11.1M
The Inhibition of HSP70 Induces Apoptosis in Pancreatic Cancer CellsR01CA124723 · NCI · UNIVERSITY OF MINNESOTA · PI GILBOA, ELI, RAMAKRISHNAN, SUNDARAM · 2007 to 2022
$4.5M
Triptolide Augments Death Receptor Mediated Apoptosis in Pancreatic CancerR01CA170946 · NCI · UNIVERSITY OF MINNESOTA · PI SALUJA, ASHOK K · 2012 to 2016
$2.4M
Functional Significance of CD133 in Pancreatic CancerR01CA184274 · NCI · UNIVERSITY OF MINNESOTA · PI BANERJEE, SULAGNA · 2014 to 2018
$1.6M
NCI NIH HHS CA124723NCI NIH HHS P50 CA101955NCI NIH HHS R01 CA124723NCI NIH HHS R01 CA170946NCI NIH HHS R01-CA170946NCI NIH HHS R01 CA184274NCI NIH HHS R01-CA184274
6 · The paper itself

Abstract

introductionOxaliplatin is part of pancreatic cancer therapy in the FOLFIRINOX or GEMOX/XELOX regimen. DNA damage repair is one of the factors responsible for oxaliplatin resistance that eventually develops in this cancer. Triptolide/Minnelide has been shown to be effective against pancreatic cancer in preclinical trials. In this study, we evaluated the efficacy of combination of triptolide and oxaliplatin against pancreatic cancer.

methodsHighly aggressive pancreatic cancer cells (MIA PaCa-2 and PANC-1) were treated with oxaliplatin (0-10 μM), low-dose triptolide (50 nM), or a combination of both for 24-48 h. Cell viability, apoptosis, and DNA damage were evaluated by appropriate methods. Nucleotide excision repair pathway components were quantitated using qPCR and Western blot. Combination of low doses of Minnelide and oxaliplatin was tested in an orthotopic murine model of pancreatic cancer.

resultsProliferation of pancreatic cancer cells was markedly inhibited by combination treatment. Triptolide potentiated apoptotic cell death induced by oxaliplatin and sensitized cancer cells towards oxaliplatin-induced DNA damage by suppressing the oxaliplatin-induced DNA damage repair pathway. Combination of low doses of Minnelide and oxaliplatin inhibited tumor progression by inducing significant apoptotic cell death in these tumors.

conclusionsCombination of low doses of Minnelide and oxaliplatin has immense potential to emerge as a novel therapeutic strategy against pancreatic cancer.

Indexed as

AnimalsAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsApoptosisCell Line, TumorCell SurvivalDiterpenesDNA DamageDNA RepairDown-RegulationEpoxy CompoundsFemaleHumansMiceOrganophosphatesOrganoplatinum Compounds14-O-phosphonooxymethyltriptolide disodium saltAntineoplastic AgentsDiterpenesEpoxy CompoundsOrganophosphatesOrganoplatinum CompoundsOxaliplatinPhenanthrenestriptolideDNA damage pancreatic cancerMinnelideNEROxaliplatinTriptolide

Identifiers

PMID26503259
PMCPMC4698020
OpenAlexW1875427287

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.